Live feed08:30:00·11mPRReleasevia QuantisnowAcrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 StudyByQuantisnow·Wall Street's wire, on your screen.ACRV· Acrivon Therapeutics Inc.Health Care
